← brief for 2026-08-30 · Slowing decline

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

Among 3,129 adults with high blood pressure and kidney disease (eGFR 25–89), finerenone slowed kidney decline by about one-third over 3.6 years — fewer people reached kidney failure or died. This was a large randomized trial subgroup, so the finding is reliable for people without diabetes.

Who did this work

Heerspink HJL · Beernink JM · Agarwal R · Cherney DZI · Lam CSP · Neuen BL · Perkovic V · Tuttle KR · Sarafidis P · Birne R · Chen X · Hornum M

Source

Article · PubMed, the drug frontier · 2026 Aug 30
https://pubmed.ncbi.nlm.nih.gov/42669052/